{"title":"The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study.","authors":"Yoshiya Tanaka, Toshiya Takahashi, Hubert van Hoogstraten, Naoto Kato, Hideto Kameda","doi":"10.1093/mr/roae055","DOIUrl":"10.1093/mr/roae055","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate unacceptable pain [UP; visual analogue scale (VAS) >40 mm] and uncontrolled inflammation [C-reactive protein (CRP) ≥1.0 mg/dL] in patients with active rheumatoid arthritis (RA) receiving sarilumab (SAR) as monotherapy or in combination with non-methotrexate conventional synthetic disease-modifying antirheumatic drugs (SAR + csDMARDs).</p><p><strong>Methods: </strong>In the HARUKA Phase 3 study (NCT02373202), Japanese patients received either SAR monotherapy (n = 61) or SAR + csDMARDs (n = 30). In this post-hoc analysis, changes in the proportions of patients with/without UP and controlled/uncontrolled inflammation were assessed over 52 weeks.</p><p><strong>Results: </strong>At baseline, 80.3% (49/61) of patients receiving SAR monotherapy had UP and this proportion decreased with treatment to 55.9% (33/59) at Week 4 and 15.5% (9/58) at Week 52. The SAR + csDMARDs group achieved a reduction in UP from 73.3% (22/30) at baseline to 34.5% (10/29) at Week 4 and 0% (0/24) by Week 52. At baseline, 34.4% (21/61) and 50% (15/30) of patients had both UP and uncontrolled inflammation in the SAR monotherapy and SAR + csDMARDs groups; by Week 2, the proportions decreased to 6.6% (4/61) and 3.3% (1/30), respectively; and 0% in both groups by Week 52.</p><p><strong>Conclusion: </strong>UP and inflammation were reduced in patients with active RA in Japan in both SAR monotherapy and SAR + csDMARDs treatment groups.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"27-33"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Subtle radiographic progression at 6 months can be detected using automated quantitative software in rheumatoid arthritis while receiving tocilizumab.","authors":"Taichi Okino, Yafei Ou, Masayuki Ikebe, Akira Furusaki, Akira Sagawa, Masaru Kato, Tatsuya Atsumi, Kenneth Sutherland, Tamotsu Kamishima","doi":"10.1093/mr/roae047","DOIUrl":"10.1093/mr/roae047","url":null,"abstract":"<p><strong>Objectives: </strong>We investigated whether our in-house software equipped with partial image phase-only correlation (PIPOC) can detect subtle radiographic joint space narrowing (JSN) progression at 6 months and predict JSN progression in rheumatoid arthritis (RA) patients receiving Tocilizumab.</p><p><strong>Methods: </strong>The study included 39 RA patients who were treated with Tocilizumab. Radiological progression of the finger joints was evaluated according to the Genant-modified Sharp score (GSS) at 0, 6, and 12 months.</p><p><strong>Results: </strong>The success rate of the software for joint space width (JSW) measurement was 96.8% (449/464). The 0-12-month JSW change by the software was significantly greater in joints with the 0-6-month PIPOC (+) group than the 0-6-month PIPOC (-) group (P < 0.001). The 0-12-month JSW change by the software was 0-12 month GSS (+) than with 0-12 month GSS (-) (P = 0.02). Here, '(+)' indicates the JSN progression during the follow-up period. Linear regression tests showed significant correlations between the 0-6 month and the 0-12 month PIPOC in the left second and third metacarpophalangeal joints (R2 = 0.554 and 0.420, respectively).</p><p><strong>Conclusions: </strong>Our in-house software equipped with PIPOC could predict subsequent JSN progression with only short-term observations.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"72-78"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review.","authors":"Takashi Ishikawa, Kenichi Nishimura, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori","doi":"10.1093/mr/roae050","DOIUrl":"10.1093/mr/roae050","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review assessed the efficacy and safety of tumor necrosis factor (TNF) inhibitors in patients with systemic juvenile idiopathic arthritis (JIA).</p><p><strong>Methods: </strong>Studies were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries (from 2000 to 2021). The risk of bias was assessed using the Cochrane Risk of Bias version 2 for randomized controlled trials (RCTs) and the manual of Minds for observational studies.</p><p><strong>Results: </strong>One RCT and 22 observational studies were included. In the RCT on infliximab, the American College of Rheumatology pediatric (ACR Pedi) 30/50/70 responses at 14 weeks were 63.8%/50.0%/22.4%, with relative risks of 1.30 [95% confidence interval (CI): 0.94-1.79]/1.48 (95% CI: 0.95-2.29)/1.89 (95% CI: 0.81-4.40), respectively. In the observational studies, ACR Pedi 30/50/70 responses for etanercept at 12 months were 76.7%/64.7%/46.4%, respectively. Infliximab treatment caused anaphylaxis in 17% and an infusion reaction in 23% of patients. The incidence of macrophage activation syndrome, serious infection, and malignancy caused by TNF inhibitors was 0-4%.</p><p><strong>Conclusions: </strong>Thus, although TNF inhibitors were relatively safe, they were unlikely to be preferentially administered in patients with systemic JIA because of their inadequate efficacy. Further studies, especially well-designed RCTs, are needed to accumulate clinical data.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"174-184"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk factor analysis of vertebral fractures requiring surgery in patients with ankylosing spondylitis.","authors":"Kazuhiro Kai, Toshifumi Fujiwara, Yukio Akasaki, Hidetoshi Tsushima, Daisuke Hara, Shinkichi Arisumi, Ryosuke Tsurui, Keitaro Yasumoto, Hirokazu Saiwai, Kenichi Kawaguchi, Hisakata Yamada, Yasuharu Nakashima","doi":"10.1093/mr/roae048","DOIUrl":"10.1093/mr/roae048","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine the risk factors for vertebral fractures requiring surgery in patients with ankylosing spondylitis (AS).</p><p><strong>Methods: </strong>We included 60 patients with AS diagnosed by using the modified New York criteria and who were treated in our department from April 2004 to March 2019. We evaluated age, sex, disease duration, C-reactive protein, erythrocyte sedimentation rate, ankylosed sacroiliac joint, bamboo spine, number of ankylosed vertebrae, and treatment (nonsteroidal anti-inflammatory drugs, prednisolone, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, and spine surgery for vertebral fracture) at the final follow-up of the nonsurgical group and the preoperative follow-up of the surgical group.</p><p><strong>Results: </strong>At the final follow-up, the mean age was 49 years, 46 patients (75%) were male, and the mean disease duration was 27 years. Additionally, 8 (13.3%) and 43 patients (71%) underwent surgical and medical treatments, respectively. The group of surgery for vertebral fracture had significantly higher C-reactive protein levels, which was also significantly associated with vertebral fracture surgery by multivariate analysis.</p><p><strong>Conclusions: </strong>C-reactive protein was identified as a risk factor for vertebral fractures requiring surgery. Control of systemic inflammation in patients with AS may reduce the risk of vertebral fractures requiring surgery.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"162-166"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review.","authors":"Kenichi Nishimura, Takashi Ishikawa, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori","doi":"10.1093/mr/roae046","DOIUrl":"10.1093/mr/roae046","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review assessed the efficacy and safety of abatacept in patients with systemic juvenile idiopathic arthritis (JIA).</p><p><strong>Methods: </strong>Studies published between 2000 and 2021 were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries. The risk of bias was assessed according to the manual for development clinical practice guidelines by Minds, a project to promote evidence-based medicine in Japan.</p><p><strong>Results: </strong>Seven observational studies were included. American College of Rheumatology pediatric 30/50/70 responses at 3, 6, and 12 months were 64.8%/50.3%/27.9%, 85.7%/71.4%/42.9%, and 80.0%/50.0%/40.0%, respectively. Outcomes on systemic symptoms, joint symptoms, and activities of daily living were not obtained. No macrophage activation syndrome or infusion reaction occurred. Serious infection occurred in 2.6% of cases.</p><p><strong>Conclusions: </strong>Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL-6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"167-173"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study.","authors":"Mayu Shiomi, Ryu Watanabe, Shogo Matsuda, Takuya Kotani, Ayana Okazaki, Yuichi Masuda, Tsuneyasu Yoshida, Mikihito Shoji, Ryosuke Tsuge, Keiichiro Kadoba, Ryosuke Hiwa, Wataru Yamamoto, Akitoshi Takeda, Yoshiaki Itoh, Motomu Hashimoto","doi":"10.1093/mr/roae044","DOIUrl":"10.1093/mr/roae044","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the current retention rate of mepolizumab (MPZ) and identify factors associated with drug retention in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in the Kansai multicentre cohort (REVEAL cohort).</p><p><strong>Methods: </strong>Sixty patients diagnosed with EGPA and treated with MPZ between December 2016 and June 2023 were enrolled. The clinical characteristics, including laboratory data, treatments administered, and disease course outcomes, were collected retrospectively. The patients were stratified into MPZ continuation (n = 53) and discontinuation (n = 7) groups, and drug retention was statistically compared using the log-rank test.</p><p><strong>Results: </strong>The median age of patients was 54.5 years, with 55% females, and 33% antineutrophil cytoplasmic antibody-positive at disease onset. MPZ exhibited a retention rate of 78.7% after 5 years. The reasons for discontinuation included treatment of coexisting diseases, inadequate response, and remission. Patient characteristics at disease onset were comparable between the groups. Patients receiving immunosuppressants (IS) before MPZ introduction demonstrated significantly higher retention rates (P = 0.038). During the final observation, the MPZ continuation group had a lower vasculitis damage index score (P = 0.027).</p><p><strong>Conclusions: </strong>MPZ exhibited a high 5-year retention rate, particularly in patients requiring IS. This study implies that long-term use of MPZ may mitigate irreversible organ damage.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"126-133"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review.","authors":"Ken-Ei Sada, Takako Miyamae, Kayoko Kaneko, Sakiko Isojima, Kunihiro Ichinose, Masakazu Matsushita, Kenji Oku, Yasunori Iwata, Keishi Fujio, Atsuko Murashima, Yoshiya Tanaka, Ayako Nakajima","doi":"10.1093/mr/roae060","DOIUrl":"10.1093/mr/roae060","url":null,"abstract":"<p><strong>Objective: </strong>This systematic scoping review assess the effect of cyclophosphamide (CY) administration during childhood on ovarian function in patients with juvenile-onset connective tissue diseases.</p><p><strong>Methods: </strong>A MEDLINE database search was conducted using terms related to CY, juvenile-onset connective tissue diseases, and ovarian function. Studies were included if they met specific criteria.</p><p><strong>Results: </strong>The search, conducted on 28 November 2023, yielded 3328 references. After a two-stage screening process, six observational studies on systemic lupus erythematosus patients were included. All studies had a high risk of confounding bias, as none adjusted for confounding variables. Two studies assessing clinical ovarian dysfunction found no clear difference between CY and non-CY groups. However, statistical differences were observed in hormonal profiles. Decreased ovarian reserve was more frequent in CY-exposed patients. Two studies showed significantly higher follicle-stimulating hormone (FSH) levels in the CY group, while one showed a trend towards higher FSH levels without statistical significance.</p><p><strong>Conclusion: </strong>This review suggested that CY use in childhood may not conclusively have clinically significant effects on ovarian function. Further investigation needed on CY's effect on hormonal levels, fertility, and pregnancy outcomes.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"88-93"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment selection in the clinical practice of systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry.","authors":"Masahiro Ayano, Naoyasu Ueda, Koji Mishima, Shun-Ichiro Ota, Kazuo Kushimoto, Atsushi Tanaka, Shotaro Kawano, Naoya Nishimura, Yusuke Kashiwado, Goro Doi, Tsuyoshi Nakayama, Ryo Fukumoto, Tomomi Tsuru, Midori Suzaki, Mitsuteru Akahoshi, Makiko Maekawa, Aya Omoto, Hitoshi Tada, Koichi Akashi, Takahiko Horiuchi, Hiroaki Niiro","doi":"10.1093/mr/roae058","DOIUrl":"10.1093/mr/roae058","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to describe the treatment selection for systemic lupus erythematosus (SLE) using data from the Kyushu Collagen Disease Network for SLE (KCDN-SLE) registry, a multicentre prospective registry in Japan.</p><p><strong>Methods: </strong>This study used data from patients registered between August 2022 and November 2023. Clinical characteristics, purpose of agent initiation, other candidate agents, and short-term efficacy and safety were evaluated.</p><p><strong>Results: </strong>We analysed 69 previously treated patients with SLE (mean age 43.7 years; 62 females, 7 males). Hydroxychloroquine, biological agents, and immunosuppressive agents were initiated during the maintenance phase in 12, 41, and 16 patients, respectively. In patients with active organ involvement, hydroxychloroquine and biological agents were widely used for initiation. In those who already achieved treatment goals, biological agents alone were predominantly selected. The SLE Disease Activity Index 2000 score and prednisolone dose declined significantly over a 6-month follow-up period. Among 48 patients with active disease, 22 achieved a lupus low disease activity state, but this had no evident association with the initiation of a biological agent. In total, 14 adverse events, predominantly infections, were observed.</p><p><strong>Conclusions: </strong>Biological agents were used preferentially, and the therapeutic agents were appropriately effective and mostly achieved the purpose of agent initiation.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"102-109"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials.","authors":"Yoshiya Tanaka, Toshiya Takahashi, Hubert van Hoogstraten, Naoto Kato, Hideto Kameda","doi":"10.1093/mr/roae057","DOIUrl":"10.1093/mr/roae057","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the efficacy and safety of sarilumab in older patients with active rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>This is a post hoc analysis of KAKEHASI (NCT02293902) and HARUKA (NCT02373202) trials with stratification by age (<65 and ≥65 years). Patients with moderately to severely active RA were treated with sarilumab in combination with methotrexate or with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy. The primary end points in KAKEHASI and HARUKA trials were the American College of Rheumatology 20% improvement criteria (ACR20) responses at Week 24 and safety, respectively. Secondary end points were other RA disease activity measures, including Clinical Disease Activity Index (CDAI).</p><p><strong>Results: </strong>Approximately 20% of patients were aged ≥65 years in treatment arms across both trials, except the sarilumab + csDMARD arm (40%, 12/30). ACR20 response rates were similar between age groups across sarilumab treatment arms, and similar results were obtained for the CDAI scores. Safety profiles were similar between age groups except for a higher incidence of serious adverse events in patients aged ≥65 years in the sarilumab + methotrexate arm.</p><p><strong>Conclusions: </strong>In Japanese patients with RA enrolled in Phase 3 studies for sarilumab, no clear difference in efficacy or safety was observed between patients aged <65 and ≥65 years.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"34-41"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Factors associated with discrepancies in disease activity as assessed by SDAI and RAPID3 in patients with rheumatoid arthritis: Data from a multicentre observational study (T-FLAG).","authors":"Mochihito Suzuki, Shuji Asai, Yoshifumi Ohashi, Yasumori Sobue, Hisato Ishikawa, Nobunori Takahashi, Kenya Terabe, Ryo Sato, Hironobu Kosugiyama, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Shiro Imagama","doi":"10.1093/mr/roae040","DOIUrl":"10.1093/mr/roae040","url":null,"abstract":"<p><strong>Objectives: </strong>The present study aimed to examine discrepancies between assessments based on Routine Assessment of Patient Index Data 3 (RAPID3) and Simple Disease Activity Index (SDAI) in rheumatoid arthritis (RA) patients with controlled disease activity.</p><p><strong>Methods: </strong>Data from 464 RA patients in SDAI remission or low disease activity (REM/LDA) were analysed. Patient-reported outcome (PRO) measures, including Health Assessment Questionnaire Disability Index (HAQ-DI), 25-question Geriatric Locomotive Function Scale (GLFS-25), and Kihon checklist (KCL), were assessed. Logistic regression models were used to identify factors associated with RAPID3 moderate or high disease activity (MDA/HDA). Cutoff values of RAPID3 MDA/HDA for each PRO evaluation item were determined using receiver operating characteristic curve analysis.</p><p><strong>Results: </strong>Among RA patients in SDAI REM/LDA, 84.9% were in RAPID3 REM/LDA. Multivariable analysis revealed that HAQ-DI, GLFS-25, and KCL were independently associated with RAPID3 MDA/HDA. Subdomain analysis of KCL revealed that activities of daily living, physical function, cognitive function, and depressive mood were significantly associated with RAPID3 MDA/HDA. Cutoff values for HAQ-DI and KCL were 0.38 and 8, respectively.</p><p><strong>Conclusions: </strong>In RA patients with controlled disease activity, discrepancies between RAPID3 and SDAI assessments were observed, with factors such as HAQ-DI, GLFS-25, and KCL being independently associated with RAPID3 MDA/HDA.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"57-63"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
